Alkermes plc - Ordinary Shares (ALKS) News
Filter ALKS News Items
ALKS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALKS News Highlights
- For ALKS, its 30 day story count is now at 15.
- Over the past 21 days, the trend for ALKS's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- TOP, BEAT and EVA are the most mentioned tickers in articles about ALKS.
Latest ALKS News From Around the Web
Below are the latest news stories about ALKERMES PLC that investors may wish to consider to help them evaluate ALKS as an investment opportunity.
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific ConferencesAlkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases, |
The Cream Of The Crop: 5 Biotech Stocks That Outrank Most StocksThe top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders. |
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingAlkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented. ARTISTRY-6 is eva |
Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination ProcessAlkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts. The preliminary proxy statement is available on the Investor Relations section of the company's website at www.alkermes.com. |
Alkermes Named Among Top 100 Companies Leading in Wellbeing by IbecNORTHAMPTON, MA / ACCESSWIRE / May 8, 2023 / Alkermes Alkermes is proud to be selected as a 2023 Top 100 Companies Leading in Wellbeing by Ibec! This recognition acknowledges companies in Ireland who are leading the way in supporting employee wellbeing. ... |
Insufficient Growth At Alkermes plc (NASDAQ:ALKS) Hampers Share PriceWith a price-to-sales (or "P/S") ratio of 4.4x Alkermes plc ( NASDAQ:ALKS ) may be sending very bullish signals at the... |
Alkermes Athlone Shortlisted for Gradirleand’s 17th Annual Graduate Recruitment AwardsAlkermes' Athlone site was recently shortlisted for gradireland's 17th annual Graduate Recruitment Awards! This award recognizes outstanding graduate intake programs across Ireland. |
Alkermes Athlone Receives Award at Ireland’s 2023 Health & Safety Excellence AwardsAlkermes Athlone site recently received a 2023 award in the Life Sciences category at Ireland's 2023 Health & Safety Excellence Awards. This recognition is a testament to our employees' focus on building a culture of safety and risk management in Athlone. |
Alkermes Inspiration Grants Now Open for ApplicationsThe 2023 Alkermes Inspiration Grants® program is now open for applications! These grants are designed to support programs or organizations for people affected by serious mental illness, addiction and cancer. |
Alkermes (ALKS) Q1 Earnings & Revenues Beat EstimatesAlkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol. |